In a remarkable example of how artificial intelligence can be used in medicine, an Australian tech professional developed an experimental cancer treatment for his pet dog using AI tools. Paul Conyngham turned to technologies like ChatGPT and Google’s AlphaFold to design a personalized vaccine after his dog was diagnosed with cancer. A devastating diagnosis for rosie Conyngham’s dog Rosie, a Staffy–Shar Pei mix adopted from an animal shelter in 2019, was diagnosed with cancer in 2021. Speaking on the Australian news program Today, Conyngham said the news was heartbreaking. He felt he had to do everything possible to help his pet survive. Rosie underwent conventional treatments such as chemotherapy, but unfortunately the tumor did not respond. As her condition worsened, Conyngham decided to explore a completely different approach. Turning to AI for answers With limited options left, Conyngham used ChatGPT to help map out a potential treatment plan. He then contacted the Ramaciotti Centre for Genomics at the University of New South Wales (UNSW) to study Rosie’s genetic data. The center sequenced her DNA at a cost of around $3,000 (roughly ₹2 lakh). Once the sequencing results came back, Conyngham compared Rosie’s healthy DNA with the DNA from the tumor. This comparison helped him identify the genetic mutations responsible for the cancer. Using AlphaFold to study the disease To better understand the cancer at a molecular level, Conyngham used AlphaFold, an AI system developed by Google DeepMind that predicts protein structures. By analyzing the proteins linked to the mutations, he was able to determine which treatments might target the tumor effectively. After gathering this information, he worked with researchers at UNSW to create a custom mRNA vaccine tailored specifically for Rosie’s cancer. Overcoming legal and ethical challenges Developing the treatment was not simple. Conyngham had to deal with regulatory and ethical approvals before the vaccine could be tested on Rosie. He spent several months securing permission for an experimental drug trial involving his own dog. Once the approvals were in place, Rosie received her first vaccine shot in December, followed by additional booster doses. Encouraging results so far Since starting the treatment, Rosie’s condition has shown noticeable improvement. Her tumor has shrunk significantly, even though the cancer was already in an advanced stage when the treatment began. Despite the promising progress, Conyngham remains realistic about the results. “I’m under no illusion that this is a cure,” he said. “But I do believe this treatment has given Rosie more time and a better quality of life.” The experiment highlights how AI tools could help develop personalized medical treatments in the future. While Rosie’s case is still experimental, it shows the growing role of artificial intelligence in tackling complex diseases like cancer.
